Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Introduction to asthma
- Definition of asthma
- What is the pathophysiology of asthma?
- What happens to the airways in asthma?
- What contributes to airway obstruction in asthma?
- Changes in the airways to clinical symptoms
- Pathology of airway inflammation in asthma
- The role of inflammation in asthma
- What factors contribute to airway inflammation in asthma?
- What are the mechanisms of airway inflammation in asthma?
- What effect does airflow obstruction have on pulmonary physiology?
- What is an asthma exacerbation or attack?
- Diagnosis of asthma
- What are risk factors for asthma?
- Age of asthma onset and clinical pattern of disease
- Asthma is a heterogeneous disease
- Clinical characteristics by asthma severity
- Measurements of pulmonary functions in asthma
- Steps in management of asthma (GINA guidelines)
- Goals of asthma management
- Treatment options for asthma
- Bronchodilators
- Inhaled corticosteroids (ICS)
- Step care approach to achieve asthma control (1)
- What is severe asthma?
- Step care approach to achieve asthma control (2)
- What biologics are used in severe asthma? (1)
- What biologics are used in severe asthma? (2)
- Case study (1)
- Case study (2)
- Case study (3)
- Summary
- Thank you
Topics Covered
- Asthma
- Corticosteroids
- GINA guidelines
- LABA
- SABA
- LAMA
- Formoterol
- Asthma diagnosis
- Asthma treatment
- Asthma comorbidities
- Asthma management
- Bronchodilator
- Eosinophilic asthma
- Neutrophilic asthma
Links
Series:
- Allergy - From Basics to Clinic
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
Talk Citation
Busse, W. and McIntyre, A. (2022, August 30). Asthma [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 10, 2024, from https://doi.org/10.69645/SAWG7208.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. William Busse has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Dr. Amanda McIntyre has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Allergy - From Basics to Clinic
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
I'm Dr. William Busse.
Amanda McIntyre and I are at
the University of
Wisconsin School of
Medicine and Public Health
in Madison, Wisconsin.
We have put together
this talk on asthma.
I will be making
the presentation.
0:17
As an introduction,
the first thing to
know about asthma
is that it is a common
respiratory disease.
It affects up to 10% of
the population worldwide,
and there are over 3 million
patients with asthma.
For most patients with asthma,
the disease begins
in early life,
usually less than
6 years of age.
This means that, for
most individuals,
asthma is a lifetime disease.
As a consequence of
being a lifetime disease
and the severity of the disease,
asthma can have a very
large health care burden
both for patients
and for society.
However, what is very
important is the understanding
that effective treatments
are available.
They're not only effective,
but they are also safe
and they can give long-lasting
benefits in the control of asthma.
1:09
The first thing to do is
to try to define asthma.
Asthma is described as a
heterogeneous disease.
That means it is more
than one disease.
It's usually characterized
by chronic airway inflammation,
is also defined by a history
of respiratory symptoms:
wheeze, shortness of breath,
chest tightness, and cough.
These are nondescript
but they vary over time
and they vary in intensity,
and together a very
important component is,
that they lead to expiratory
airflow limitation.
The definition of asthma
is very non-specific,
but is characterized by
having variable symptoms of
cough, wheezing, and
shortness of breath.
There are variabilities in
the intensity of the disease
but an underlying
characteristic feature
is airway inflammation.